Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy

Inclusion Criteria: * Patients diagnosed with type 1 or 2 diabetes mellitus * Patients diagnosed with DME with central involvement (defined as the area of the center subfield of optical coherence tomography \[OCT\]) * Patients for whom the decision has been made to treat with an approved anti-VEGF therapy prior to inclusion into the study * Patients who received the first approved intravitreal anti VEGF treatment from October 01, 2012 * Patients who give informed consent in writing for study participation Exclusion Criteria: * Treatment with any anti-VEGF therapy prior to the start of the observation period (October 01, 2012) or enrolment into the study * Participation in an investigational program with interventions out of clinical routine practice